
The zzso chemistry, zzso clinical studies, and adverse effects of zzso an zzso zzso agent, are zzso zzso mechanism of action is not clearly zzso although the drug is known to inhibit DNA zzso As an zzso zzso zzso zzso agent, zzso is available to physicians for the treatment of adult patients with zzso acute zzso leukemia zzso under an established zzso Following intravenous administration, zzso has a zzso plasma zzso It is extensively zzso by the liver to inactive compounds that are zzso in the zzso Phase I studies indicated that zzso was potentially effective in patients with solid tumors and acute zzso Patients with solid tumors could tolerate much lower doses of zzso than leukemia patients because of zzso bone-marrow suppression in the zzso In Phase II studies, zzso appeared effective in treating the acute zzso with response rates of zzso and zzso for acute zzso leukemia and zzso zzso Patients with other types of zzso have not responded to zzso zzso Frequently occurring adverse effects of zzso include zzso and zzso in patients with solid zzso zzso zzso and zzso zzso in patients receiving higher doses zzso zzso zzso zzso and zzso The clinical usefulness of zzso appears limited to treatment of the acute zzso Studies of combination therapies that include zzso are currently zzso and should further define the therapeutic role of zzso 

